Sei Investments Co. Makes New $624,000 Investment in Biodesix, Inc. $BDSX

Sei Investments Co. acquired a new stake in Biodesix, Inc. (NASDAQ:BDSX) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 43,024 shares of the company’s stock, valued at approximately $624,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BDSX. AIGH Capital Management LLC bought a new stake in shares of Biodesix in the first quarter valued at approximately $10,996,000. Thompson Davis & CO. Inc. acquired a new stake in Biodesix during the first quarter worth approximately $170,000. Monashee Investment Management LLC increased its stake in Biodesix by 12.3% during the 4th quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock worth $764,000 after acquiring an additional 12,348 shares during the period. Geode Capital Management LLC increased its stake in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares during the period. Finally, Trexquant Investment LP acquired a new position in Biodesix in the 4th quarter valued at $187,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Biodesix Stock Performance

Shares of Biodesix stock opened at $24.00 on Friday. The company has a 50 day moving average of $20.50 and a 200-day moving average of $16.19. Biodesix, Inc. has a 1-year low of $5.26 and a 1-year high of $25.52. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 5.12. The company has a market cap of $253.20 million, a PE ratio of -7.57 and a beta of 0.56.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.19. The business had revenue of $26.86 million for the quarter, compared to analysts’ expectations of $26.03 million. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. As a group, equities research analysts forecast that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Biodesix news, Director Jack W. Schuler bought 15,000 shares of Biodesix stock in a transaction on Wednesday, August 12th. The shares were purchased at an average price of $24.47 per share, with a total value of $367,050.00. Following the acquisition, the director owned 555,810 shares in the company, valued at $13,600,670.70. This trade represents a 2.77% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders acquired 42,600 shares of company stock worth $1,033,062 in the last three months. 23.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BDSX has been the subject of a number of recent analyst reports. Roth Capital started coverage on Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $27.00 price target (up from $26.00) on shares of Biodesix in a research report on Thursday, August 6th. Canaccord Genuity Group raised their price target on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.33.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.